Subsea 7 - 4Q22 and FY22 conference call notification
Luxembourg –18 January 2023 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) will publish its fourth quarter results for the period ended 31 December 2022 on 2 March 2023 at 08:00 CET.
From 08:00 CET the results announcement and presentation will be available at www.subsea7.com.
A conference call and simultaneous webcast for the investment community will be held on 2 March 2023 at 13:00 CET.
Conference call information:
Date: 2 March 2023
Time: 12:00 GMT / 13:00 CET
Conference call registration:
Phone dial-in: https://register.vevent.com/register/BI168b055453614ec7809c9f72edb6876c
Webcast: https://edge.media-server.com/mmc/p/unwkh4rt
******************************************************************************
Subsea7 is a global leader in the delivery of offshore projects and services for the evolving energy industry creating sustainable value by being the industry’s partner and employer of choice in delivering the efficient offshore solutions the world needs.
Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62.
******************************************************************************
Contact:
Katherine Tonks
Head of Investor Relations
Subsea 7 S.A.
Tel +44 20 8210 5568
katherine.tonks@subsea7.com
www.subsea7.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Prepayments, Realkredit Danmark A/S6.5.2024 11:12:01 CEST | Press release
To Nasdaq Copenhagen A/SExecutive Management Bernstorffsgade 40 DK-1577 København V www.rd.dk Telephone +45 7012 5300 6 May 2024 Company Announcement No 34/2024 Prepayments, Realkredit Danmark A/S Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes prepayments as of Friday 3 May 2024. Please find the data in the attached file. The information will also be available on www.rd.dk. Yours sincerely The Executive Management Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068. Attachments Nr 34_Ekstraordinaere indfrielser_ukBilag til selskabsmeddelelse nr 34-2024
Ekstraordinære indfrielser, Realkredit Danmark A/S6.5.2024 11:12:01 CEST | pressemeddelelse
Til Nasdaq Copenhagen A/SDirektionen Bernstorffsgade 40 1577 København V www.rd.dk Telefon 7012 5300 6. maj 2024 Selskabsmeddelelse nummer 34/2024 Ekstraordinære indfrielser, Realkredit Danmark A/S I medfør af lov om kapitalmarkeder §24 oplyses hermed om ekstraordinære indfrielser vedrørende Realkredit Danmark A/S pr. fredag den 3. maj 2024. Oplysningerne fremgår af vedhæftede datafil. Oplysningerne vil desuden kunne ses på Realkredit Danmarks hjemmeside på www.rd.dk. For yderligere informationer om dataformat og –indhold henvises til Nasdaq Copenhagen A/S’s hjemmeside. Med venlig hilsen Direktionen Eventuel henvendelse kan rettes til chefanalytiker Hella Gebhardt Rønnebæk, 45 13 20 68. Vedhæftede filer Nr. 34_Ekstraordinaere indfrielser_dkBilag til selskabsmeddelelse nr 34-2024
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia6.5.2024 11:00:00 CEST | Press release
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1 DMI is a common, irreversible complication of diabetic retinopathy (DR) that may lead to blindness.12,3,4 It can develop when the light sensitive tissues of the central retina do not receive adequate blood supply over a longer time. There are currently no approved treatments for DMI. The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasive laser treatment. However, some patients’ conditions progress despite this treatment.5 BI 764524 uses a novel mode of action by inhibiting the Sema3A pathway to re-vascularize ischemic areas and potentia
Orion Corporation: Managers’ transactions – Eija Ronkainen6.5.2024 11:00:00 CEST | Press release
ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Eija Ronkainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Eija Ronkainen Position: Member of the Board/Deputy member Issuer: Orion Oyj LEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATION Reference number: 61636/4/4 ____________________________________________ Transaction date: 2024-05-03 Outside a trading venue Instrument type: SHARE ISIN: FI0009014377 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 556 Unit price: 0 EUR Aggregated transactions (1): Volume: 556 Volume weighted average price: 0 EUR Ori
Orion Corporation: Managers’ transactions – Henrik Stenqvist6.5.2024 11:00:00 CEST | Press release
ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Henrik Stenqvist Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Henrik Stenqvist Position: Member of the Board/Deputy member Issuer: Orion Oyj LEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATION Reference number: 61645/4/4 ____________________________________________ Transaction date: 2024-05-03 Outside a trading venue Instrument type: SHARE ISIN: FI0009014377 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 556 Unit price: 0 EUR Aggregated transactions (1): Volume: 556 Volume weighted average price: 0 EUR